Moraxella bovis and Infectious Bovine Keratoconjunctivitis (Pinkeye): Diagnosis and Management

Introduction

Infectious bovine keratoconjunctivitis (IBK), commonly termed pinkeye, is the most economically significant ocular disease of cattle worldwide. The condition is characterized by lacrimation, conjunctival hyperemia, corneal edema, ulceration, and in severe cases, perforation and blindness. Moraxella bovis has historically been recognized as the primary etiological agent, but recent molecular and genomic studies have identified other pathogenic Moraxella species including Moraxella bovoculi and Moraxella oculi as contributing or alternative causative agents [1, 2, 3, 30]. The clinical and diagnostic complexity of IBK necessitates a thorough understanding of the bacterial pathogens involved, host risk factors, environmental influences, and evidence-based control strategies.

Etiology

Moraxella bovis

Moraxella bovis is a Gram-negative, aerobic, non-motile coccobacillus belonging to the family Moraxellaceae. Pathogenic strains possess two key virulence determinants: type IV pili (fimbriae) and a secreted repeat-in-toxin (RTX) cytotoxin designated MbxA [4, 5, 6, 30]. The pili mediate attachment to corneal epithelial cells, while the RTX toxin causes cell lysis and corneal ulceration. Genomic analysis of M. bovis strains from North America has revealed two major genotypes with distinct genetic determinants, including differences in pilin genes and toxin production [6]. The presence of polysialic acid and chondroitin-like polysaccharides on the cell surface has also been identified as a potential virulence factor that may aid in immune evasion [4].

Moraxella bovoculi and Moraxella oculi

Moraxella bovoculi is frequently isolated from IBK-affected eyes, either alone or in co-infection with M. bovis [1, 7, 8]. This species carries a separate RTX toxin (MbvA) and exhibits genetic diversity in its type IV pilin (PilA) across geographically distinct isolates [34, 35]. Moraxella oculi was formally described as a novel species from a cow with IBK in the United States [3] and has since been reported in Brazil [2]. The simultaneous identification of M. bovoculi and M. bovis in one-humped camels (Camelus dromedarius) in the Sahara Desert indicates that these pathogens are not restricted to cattle and may have a broader ungulate host range [9].

Other Bacteria Implicated in IBK

The ocular microbiome of cattle includes numerous other bacteria that may act as secondary invaders or contribute to disease severity. Species such as Mycoplasma bovoculi, Neisseria spp., and various commensals have been recovered from IBK cases [10, 29]. However, the presence of hemolytic Moraxella species remains the strongest microbiological correlate of clinical disease [1, 11, 30]. Genetic host factors also influence the composition of the ocular microbiome in preweaned beef calves, which may affect susceptibility [12].

Epidemiology

IBK occurs in both beef and dairy cattle, with higher incidence in young stock and animals raised under intensive management. Environmental factors play a critical role in disease expression. Ultraviolet (UV) radiation from sunlight, high ambient temperatures, dust, and the presence of face flies (Musca autumnalis) are well-established predisposing factors [28]. Face flies mechanically transmit Moraxella species from infected to susceptible eyes and cause conjunctival irritation that facilitates bacterial colonization.

Cohort studies in dairy heifers under Mediterranean climatic conditions have identified seasonality and animal age as significant predictors of IBK incidence [13]. Cross-sectional surveys in the same region confirm that herd-level prevalence is influenced by housing systems, ventilation, and exposure to flies [14]. Dust and wind further contribute to ocular surface damage.

Clinical Signs

The clinical presentation of IBK ranges from mild serous conjunctivitis to severe suppurative keratitis with corneal ulceration. The disease typically begins with epiphora, photophobia, and blepharospasm. A central corneal ulcer appears within 24 to 72 hours, often accompanied by corneal edema and neovascularization. In uncomplicated cases, healing occurs over 2 to 3 weeks with residual corneal scarring (leukoma). Severe cases may progress to descemetocele, corneal rupture, and panophthalmitis leading to vision loss [33]. Bilateral involvement is common but often asymmetrical.

The clinical definition of IBK has been standardized to include observable corneal ulceration as a minimum criterion for case classification in research settings [33]. This definition aids in differentiating IBK from other causes of ocular discharge such as foreign bodies, entropion, or Thelazia infection.

Pathology

The pathological hallmark of IBK is corneal epithelial erosion with exposure of the underlying stroma. Histologically, there is infiltration of neutrophils and mononuclear cells into the cornea and conjunctiva. The RTX cytotoxin produced by M. bovis and M. bovoculi induces pore formation in corneal epithelial cell membranes, leading to cell death and stromal matrix degradation [30]. Corneal neovascularization is a reparative response but also contributes to scarring. In perforated cases, the anterior chamber is lost and the lens may become involved.

Diagnosis

The diagnostic workup for IBK should integrate clinical examination with laboratory confirmation of the causative Moraxella species. The following approaches are recommended.

Clinical Diagnosis

A presumptive diagnosis of IBK is made based on the presence of corneal ulceration combined with conjunctivitis and lacrimation. Differential diagnoses include foreign body keratitis, entropion, congenital corneal dystrophy, and infection with other pathogens such as bovine herpesvirus type 1 (BHV-1) or Mycoplasma bovis. A decision tree for diagnostic workup is presented in Figure 1.

flowchart TD
    A["Clinical Signs: Ocular discharge, blepharospasm, corneal opacity"], > B["Corneal ulcer present?"]
    B, >|Yes| C["Presumptive IBK"]
    B, >|No| D["Consider foreign body, entropion, viral keratitis"]
    C, > E["Collect conjunctival swab for laboratory testing"]
    E, > F["Culture on blood agar (hemolysis)"]
    E, > G["Molecular testing: Real-time PCR or targeted NGS"]
    F, > H["Moraxella spp. identified?"]
    G, > H
    H, >|Yes| I["Confirmed IBK: species-level identification (M. bovis, M. bovoculi, M. oculi)"]
    H, >|No| J["Consider other causes: BHV-1, Mycoplasma, fungi"]
    I, > K["Antimicrobial sensitivity testing recommended"]
    K, > L["Select treatment: topical or systemic antimicrobial"]
    L, > M["Monitor for healing; consider vaccination for herd-level control"]

Sample Collection and Transport

Specimens are collected using sterile cotton swabs from the ventral conjunctival fornix or the margin of an active corneal ulcer. A comparative evaluation of transport buffers found that Amies with charcoal provides superior preservation of M. bovis and M. bovoculi viability compared to other media [15]. Swabs should be transported at 4 degrees Celsius and processed within 24 hours.

Culture and Phenotypic Identification

Moraxella species grow well on sheep blood agar at 35 to 37 degrees Celsius. Colonies appear as small, round, gray-white, and are typically beta-hemolytic. Hemolysis is a key marker for pathogenic strains. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) provides rapid and reliable identification at the species level and can differentiate M. bovis from M. bovoculi [7, 5, 34]. Supplementing agar with calcium chloride enhances the detection of RTX toxin phenotypes [34]. Biochemical tests are less discriminating but can be used if MALDI-TOF is unavailable.

Molecular Diagnostics

Molecular methods have become the gold standard for definitive diagnosis and differentiation of Moraxella species.

Real-time multiplex PCR. A multiplex real-time PCR assay targeting species-specific genes allows simultaneous detection of M. bovis, M. bovoculi, and M. oculi from ocular swabs [16]. This method is highly sensitive and can be performed on swabs stored in transport buffer.

Targeted next-generation sequencing (tNGS). A tNGS assay that amplifies and sequences multiple genomic loci has been developed to detect all three Moraxella species directly from clinical specimens [17]. This approach provides higher resolution for mixed infections and strain typing.

Whole genome sequencing (WGS). WGS has been applied to characterize M. bovis genotypes and virulence gene content from North American and Uruguayan isolates [8, 6]. WGS also enables the identification of antimicrobial resistance determinants and phylogenetic relationships.

16S rRNA gene sequencing. Amplicon sequencing of the 16S rRNA gene can identify Moraxella species but may not reliably separate M. bovis from M. bovoculi due to sequence similarity. However, it remains useful for profiling the broader ocular bacterial community in IBK cases [7, 10, 11].

Emerging Diagnostic Tools

MALDI-TOF MS has been used to construct genotype classification models for M. bovis based on protein profiles [5]. For M. bovoculi, biomarker detection models can distinguish RTX toxin phenotypes using calcium-supplemented agar [34]. These tools may eventually allow point-of-care prediction of virulence potential.

Treatment

The management of IBK focuses on antimicrobial therapy to eliminate Moraxella organisms and supportive care to facilitate corneal healing.

Antimicrobial Therapy

Topical ophthalmic preparations containing oxytetracycline, florfenicol, or tulathromycin are commonly used. Subconjunctival injections of antibiotics may be administered in severe cases. Systemic treatment with long-acting oxytetracycline or tulathromycin is also effective, particularly when topical administration is impractical due to animal temperament or herd size. Antimicrobial resistance has been documented in M. bovis and M. bovoculi isolates, necessitating sensitivity testing before treatment in recurrent outbreaks [7].

Novel Therapeutic Approaches

Ultraviolet C (UVC) light. In vitro studies have demonstrated that UVC light at 254 nm has potent bactericidal activity against M. bovis, offering a potential non-antibiotic treatment option [18].

Photodynamic therapy (PDT). Porphyrin-based photosensitizers combined with visible light produce reactive oxygen species that kill Moraxella spp. in both planktonic and biofilm states. Water-soluble tetra-cationic porphyrins have shown efficacy in vitro and ex vivo [19, 20].

Anti-biofilm strategies. Moraxella species can form biofilms on the corneal surface. PDT and certain cationic agents have demonstrated antibiofilm action that may enhance antimicrobial penetration [19].

Non-Antimicrobial Approaches

A scoping review of non-antimicrobial strategies for IBK prevention and treatment in cow-calf operations identified fly control, UV-blocking eye patches, and topical lubricants as supportive measures [26]. These approaches reduce environmental and mechanical insults to the cornea and can decrease disease incidence at the herd level.

Control and Prevention

Vaccination

Vaccination against M. bovis has been attempted using bacterins, pilus-based vaccines, and RTX toxoid vaccines. The efficacy of commercial and autogenous vaccines has been evaluated in multiple randomized controlled trials [21, 22, 23, 27]. A five-year trial comparing a commercial and an autogenous vaccine found variable antibody responses and limited field efficacy [23]. An intranasal M. bovis cytotoxin vaccine showed some reduction in IBK incidence in a controlled field trial [21]. In Australian beef cattle, a commercial pinkeye vaccine did not significantly reduce disease risk in a randomized trial [22]. Overall, the evidence base for vaccination remains mixed, and no single vaccine has consistently demonstrated high protection across different environments [27]. Bovine immune responses to M. bovis and M. bovoculi following vaccination are influenced by strain variation, route of administration, and the inclusion of multiple antigens [32].

Herd Management and Environmental Control

Reducing exposure to flies, dust, and UV radiation is critical. Fly control methods include insecticide-impregnated ear tags, pour-on insecticides, and biological control. Pasture management that minimizes long-stem grass and dusty conditions helps reduce ocular irritation. Providing shade or shelter during peak UV hours can decrease disease pressure [28]. Because genetic factors influence ocular microbiome composition and likely susceptibility to IBK, selective breeding for resistance may be a future consideration [12].

Biosecurity

Quarantine of newly introduced animals and separation of affected from unaffected groups can limit the spread of Moraxella species within a herd. Although M. bovis and M. bovoculi are not highly persistent in the environment, sharing of equipment and personnel between affected and naive animals should be avoided.

Conclusion

Infectious bovine keratoconjunctivitis remains a multifactorial disease with Moraxella bovis, Moraxella bovoculi, and Moraxella oculi as the primary bacterial incitants. Accurate diagnosis requires integration of clinical examination, culture, and molecular methods such as real-time multiplex PCR or targeted next-generation sequencing. Treatment should be guided by antimicrobial sensitivity patterns, and novel therapies including UVC light and photodynamic therapy show promise for reducing antibiotic use. Control relies on a combination of vaccination, fly management, environmental modification, and biosecurity. Continued genomic surveillance will be essential to understand the evolution of virulence and resistance in these pathogens.

References

[1] Zbrun MV, Alvarado W, Peña A et al. Infectious bovine keratoconjunctivitis in dairy herds: Presence of haemolytic Moraxella bovis and Moraxella bovoculi. Res Vet Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/42070394/

[2] de Carvalho CV, Domingues R, de Carvalho Coutinho C et al. First report of Moraxella oculi in Brazil in an infectious bovine keratoconjunctivitis outbreak. Vet Res Commun. 2025. https://pubmed.ncbi.nlm.nih.gov/40106178/

[3] Wilkes RP, Anis E, Kattoor JJ. Moraxella oculi sp. nov., isolated from a cow with infectious bovine keratoconjunctivitis. Int J Syst Evol Microbiol. 2024. https://pubmed.ncbi.nlm.nih.gov/38415687/

[4] Vionnet J, Peterson DC, Loy JD et al. Identification of Polysialic Acid and Chondroitin-like Polysaccharides of Moraxella bovis Strains Associated with Infectious Bovine Keratoconjunctivitis. ACS Infect Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/41343704/

[5] Olson HG, Loy JD, Clawson ML et al. Genotype classification of Moraxella bovis using MALDI-TOF MS profiles. Front Microbiol. 2022. https://pubmed.ncbi.nlm.nih.gov/36569069/

[6] Wynn EL, Hille MM, Loy JD et al. Whole genome sequencing of Moraxella bovis strains from North America reveals two genotypes with different genetic determinants. BMC Microbiol. 2022. https://pubmed.ncbi.nlm.nih.gov/36271336/

[7] Yalcin S, Cigerci IS, Ozgen A et al. Genetic diversity, virulence genes, and antimicrobial resistance of Moraxella bovoculi and Moraxella bovis from infectious bovine keratoconjunctivitis: insights from MALDI-TOF-MS, 16S rRNA analyses, and other ocular bacteria. Vet Res Commun. 2025. https://pubmed.ncbi.nlm.nih.gov/41307778/

[8] Bilbao L, Acquistapace S, Umpiérrez A et al. Genomic characterization of Moraxella bovis and Moraxella bovoculi Uruguayan strains isolated from calves with infectious bovine keratoconjunctivitis. Rev Argent Microbiol. 2024. https://pubmed.ncbi.nlm.nih.gov/38403533/

[9] Ramo MLÁ, Lamin SM, Mustafa L et al. First simultaneous identification of Moraxella bovoculi and Moraxella bovis in one-humped camel (Camelus dromedaries) in the Sahara Desert. Trop Anim Health Prod. 2026. https://pubmed.ncbi.nlm.nih.gov/41528399/

[10] Gafen HB, Liu CC, Ineck NE et al. Alterations to the bovine bacterial ocular surface microbiome in the context of infectious bovine keratoconjunctivitis. Anim Microbiome. 2023. https://pubmed.ncbi.nlm.nih.gov/37996960/

[11] Anis E, Kattoor JJ, Greening SS et al. Investigation of the pathogens contributing to naturally occurring outbreaks of infectious bovine keratoconjunctivitis (pinkeye) using Next Generation Sequencing. Vet Microbiol. 2023. https://pubmed.ncbi.nlm.nih.gov/37104939/

[12] Lakamp AD, Neujahr AC, Hille MM et al. Genetic influence on the composition of the ocular microbiome in preweaned beef calves. J Anim Sci. 2025. https://pubmed.ncbi.nlm.nih.gov/40319373/

[13] Maartens LH, Gummow B, Grewar JD et al. A cohort study of factors associated with the incidence rate of keratoconjunctivitis in dairy heifers farmed under Mediterranean climatic conditions. Prev Vet Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41831253/

[14] Maartens LH, Thompson PN, Grewar JD et al. A cross-sectional study of keratoconjunctivitis among dairy cattle farms subject to Mediterranean climatic conditions. Trop Anim Health Prod. 2025. https://pubmed.ncbi.nlm.nih.gov/40131538/

[15] Maartens LH, Gummow B, Grewar JD et al. An evaluation of alternative buffers for the transport and detection of Moraxella bovis and M. bovoculi on cotton wool swabs. Res Vet Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/41547199/

[16] Strochkov V, Sattarova R, Boranbayeva K et al. Development and evaluation of a multiplex polymerase chain reaction in real-time for differential diagnosis of Moraxella-induced keratoconjunctivitis in livestock. Vet World. 2023. https://pubmed.ncbi.nlm.nih.gov/38328358/

[17] Wilkes RP, Kattoor JJ, Weng HY et al. Targeted next-generation sequencing assay to detect 3 Moraxella spp. directly from bovine ocular swabs. J Vet Diagn Invest. 2024. https://pubmed.ncbi.nlm.nih.gov/38018659/

[18] Turicea B, Sahoo DK, Allbaugh RA et al. Antimicrobial Activity of Ultraviolet C Light as a Potential Novel Treatment for Moraxella bovis Infection-An In Vitro Study. Vet Ophthalmol. 2026. https://pubmed.ncbi.nlm.nih.gov/41047748/

[19] Seeger MG, Iglesias BA, Vogel FSF et al. Antibiofilm action using water-soluble tetra-cationic porphyrin and antibacterial photodynamic therapy against Moraxella spp. from cattle. Microb Pathog. 2023. https://pubmed.ncbi.nlm.nih.gov/36948363/

[20] Seeger MG, Machado CS, Iglesias BA et al. Antimicrobial efficacy of in vitro and ex vivo photodynamic therapy using porphyrins against Moraxella spp. isolated from bovine keratoconjunctivitis. World J Microbiol Biotechnol. 2022. https://pubmed.ncbi.nlm.nih.gov/35501420/

[21] Angelos JA, Agulto RL, Mandzyuk B et al. Randomized controlled field trial to assess the efficacy of an intranasal Moraxella bovis cytotoxin vaccine against naturally occurring infectious bovine keratoconjunctivitis. Vaccine X. 2023. https://pubmed.ncbi.nlm.nih.gov/37693844/

[22] Kneipp M, Green AC, Govendir M et al. A randomised control trial to evaluate the effectiveness of a commercial vaccine for pinkeye in Australian beef cattle. Prev Vet Med. 2023. https://pubmed.ncbi.nlm.nih.gov/36512867/

[23] Hille MM, Spangler ML, Clawson ML et al. A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis. Vaccines (Basel). 2022. https://pubmed.ncbi.nlm.nih.gov/35746524/

[24] Kuibagarov M, Abdullina E, Ryskeldina A et al. Association of different microbes and pathogenic factors in cases of infectious bovine keratoconjunctivitis in cattle from Eastern Kazakhstan. Vet World. 2023. https://pubmed.ncbi.nlm.nih.gov/37859972/

[25] Ivanov NP, Bakiyeva FA, Namet AM et al. The epizootic situation of cattle moraxell